The University of Chicago Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of Sweis, Randy
PropertyValue
overview Dr. Sweis is a physician-scientist working to identify and circumvent mechanisms of resistance to cancer immunotherapies. His laboratory research is focused on modulating the tumor microenvironment to facilitate anti-tumor immune responses, using mouse models of bladder and skin cancers. In the clinic, he uses his expertise in developmental therapeutics and clinical pharmacology to investigate biomarkers and novel therapeutic strategies to improve immunotherapy efficacy in patients.
One or more keywords matched the following items that are connected to Sweis, Randy
Item TypeName
Concept Urinary Bladder
Concept Urinary Bladder Neoplasms
Academic Article Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer.
Academic Article Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Academic Article Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.
Grant Elucidating immunotherapy resistance mechanisms in non-T cell-inflamed bladder cancer
Academic Article Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer.
Academic Article Methods to assess anticancer immune responses in orthotopic bladder carcinomas.
Academic Article Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies.
Academic Article FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer.
Academic Article The Urinary Microbiome and Bladder Cancer: Susceptibility and Immune Responsiveness.
Academic Article Multi-step screening of neoantigens' HLA- and TCR-interfaces improves prediction of survival.
Academic Article The Tumor Microenvironment of Bladder Cancer.
Academic Article A validated mathematical model of FGFR3-mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer.
Academic Article Clinical Activity of Olaparib in Urothelial Bladder Cancer With DNA Damage Response Gene Mutations.
Academic Article A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
Academic Article Bladder-Preserving Trimodality Therapy With Capecitabine.
Academic Article Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.
Academic Article Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial.
Search Criteria
  • Urinary Bladder